

On company's stationary

COMMITMENT LETTER
Principles for Responsible Clinical Trial Data Sharing

We, leaders of the pharmaceutical industry, believe that:

- Our commitment to data sharing will enhance research and scientific knowledge, advance patient care and improve public health;
- The dramatic increase in the amount of information that research-based companies will make available to researchers will enhance collaborations in the interest of improved research;
- The interests of patients remain at the heart of everything we do in relation to responsible clinical trial data sharing;
- The industry must be allowed to flourish in order to fulfill its promise in serving patients, past, present and future.

On behalf of Novo Nordisk A/S, I hereby confirm our adherence to the Principles for Responsible Clinical Data Sharing launched by PhRMA and EFPIA. We are therefore committed to:

- Establishing policies, procedures or guidelines to reflect the commitments of the Principles;
- Ensuring that relevant employees have received information and training on the Principles; and
- Considering and planning the steps it will take to monitor compliance with the commitments of the Principles on an ongoing basis.

We also adhere to the EFPIA's decision to ensure that an adequate code is in place by mid-2015, which will allow monitoring and oversight of the companies' compliance with the Principles.

Company: Novo Nordisk A/S

Signed on behalf of the company by

Name : Kingo First name: Lise

Position in the company: Executive Vice President
Representing and engaging the company in regard of its EFPIA membership obligations

Date 2014-06-05

Signature 